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Abstract  Background: Measurements of CD4 and haemoglobin are used to determine the immunological state and 
information about disease progression for HIV-infected patients. Use of BD FACS Presto™ point of care (POC) device for 
CD4 and haemoglobin (Hb) determination can significantly improve access, uptake and coverage of laboratory services and 
hence management of HIV-infected patients in resource-limited settings. This study evaluated the relative bias in CD4 and 
Hb measurements using BD FACSPresto™ system compared to BD FACSCalibur™ CD4 analyser and Mindray BC-5380 
haematology analyser respectively based on venous and capillary blood samples in a clinical hospital setting. Methods: 
Venous and capillary blood samples were used to determine CD4 counts and Hb levels among HIV-1 infected patients. The 
samples were analysed on the BD FACSPresto™ and results compared against BD FACSCalibur™ and Mindray BC-5380 
for CD4 and haematology analyser respectively. Results: Results for absolute CD4 counts in both venous and capillary blood 
showed a high correlation (R2 = 0.922, P < 0.001) when they were analysed on BD FACSPresto™ and BD FACSCalibur™ 
machines. Overall, the mean difference in absolute CD4 count was 77.16 cells/mL (95%CI: 49.89, 104.42, p<0.01) when 
analysed on two platforms. The BD FACSCalibur™ gave a higher mean of absolute CD4 count (834.38 cells/ml) compared 
to BD FACSPresto™ (757.23 cells/ml) when venous sample type is used. There was a significant mean difference of Hb 
levels at 0.31 (P <0.001) between the two sample types when analysed on BD FACSPresto™ and Mindray BC-5380 
haematology analyser. In addition, there was a high correlation (R2 = 0.920, P < 0.001) of Hb level measurements between 
the BD FACSPresto™ and Mindray BC-5380 haematology analyser. Conclusion: The BD FACSPresto performed 
satisfactorily in comparison to the conventional reference standard technologies. Venous and capillary blood sample types 
showed a high correlation when analysed for absolute CD4 count and Hb using BD FACSPresto™, BD FACSCalibur™ and 
Mindray BC-5380 haematology analyser. BD FACSPresto capillary platform can be used interchangeably with BD 
FACSCalibur™ venous platform for CD4 and Mindray BC-5380 for Hb measurement in resource limited settings to increase 
access and uptake of laboratory services. 
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1. Introduction 
Infection with HIV is mediated primarily through binding 
of viral envelope molecule gp120 to the cluster of 
differentiation (CD) 4 cell surface glycoprotein [1, 2]. A 
decrease in the number of CD4+ T cells is thus closely 
related to disease progression and increased risk of 
contracting opportunistic infections in HIV-infected patients 
[3]. Reconstitution of the CD4+ T cell population is achieved  
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over time after initiation of antiretroviral treatment [4, 5]. 
Quantification of CD4+ T lymphocytes in peripheral blood is, 
therefore, critical for the evaluation and monitoring of 
patients with HIV. In fact, the WHO recommends CD4 
counts be used to enable differentiated care for diagnosis of 
drug failure where routine viral load is not feasible [6, 7]. 
In Kenya, CD4 measurements are used to support 
differential care in the national HIV program as stated in the 
recently launched “Test and Treat” guidelines [7]. The assay 
is used for determining the immunological stage of HIV 
infection, to obtain information about disease progression, 
identification of patients likely to benefit from cotrimoxazole 
or dapsone prophylaxis, patients most at risk of developing 
immune reconstitution syndrome, vaccine guidance and 
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ARV regimen selection. In addition, CD4 counts may be 
used for optimal evaluation of treatment response and   
early detection of opportunistic co-infections such as 
Cryptococcus neoformans (CrAg) in patients with <100 CD4 
T cells/μl. CD4 measurement tests are thus encouraged by 
WHO where feasible to improve the quality of HIV 
prevention, care and treatment programs. The standard 
method for determination of CD4 percentage and absolute 
cell counts is flow cytometry. 
Disease progression in HIV-infected patients also results 
in haematological abnormalities including anaemia which is 
caused by various factors including nutritional deficiencies, 
neoplastic diseases and myelosuppressive medication such 
as zidovudine (AZT) and dapsone [8]. Low haemoglobin 
(Hb) levels are associated with increased risk of mortality 
which is independent of CD4 counts or viral load [9-11]. 
Anaemia also correlates with low CD4 counts, low body 
mass indices (BMI) and reduced quality of life [12]. Hb 
measurements are therefore used in ART regimen selection 
where AZT is excluded if baseline Hb level is below 9.5g/dL 
or substituted if subsequent measurements show a decline 
below baseline levels or less than 8.5g/dL. In addition, where 
dapsone is used as a substitute for cotrimoxazole for 
Pneumocystis carinii pneumonia, Hb must be monitored [7]. 
Thus although the gold standard disease progression markers 
are viral load and CD4 counts, haemoglobin levels are also 
used in clinical management of people living with HIV. 
Unlike haemoglobin level determination, CD4 
enumeration remains largely inaccessible in resource-limited 
settings, including Kenya due to poor health infrastructure 
and poor laboratory inventory systems resulting in 
stock-outs of laboratory consumables. Most clinical 
laboratories in developing countries are often unsuitable for 
routine determination of CD4. High costs of equipment, 
reagents and challenges associated with machine 
maintenance further restrict access [13, 14]. Other 
limitations include, poor nutritional status of patients making 
it difficult to obtain adequate venous blood draws for 
analysis and insufficient numbers of trained staff on venous 
phlebotomy. Moreover, there is a scarcity of educators and 
training programs, inadequate logistical support and 
insufficient monitoring of test quality.  
To address these shortfalls in resource limited settings, 
significant investments need to be directed towards 
improving access to improved laboratory infrastructure. 
Such measures include developing laboratory capacity and 
deploying point-of-care technologies (POCTs) such as the 
BD FACSPresto™ which can measure both haemoglobin 
levels and CD4+ T cells. These efforts aim to reduce 
turnaround time for results and present the possibility of 
CD4 testing as soon as the diagnosis of HIV is confirmed 
thereby improving patient retention. Introduction of cost 
effective point-of-care CD4+ cell counters has improved 
access to quick and reliable CD4+ T-cell counts in 
HIV-positive patients [15, 16]. In terms of economic 
evaluation, it’s been indicated using a simulation model of 
HIV disease, that a POC CD4 strategy of immunological 
staging results in nearly one full year of additional life 
expectancy compared to LAB-CD4 and is near the very 
cost-effective [17-19]. It is, therefore, important to evaluate 
existing and emerging POC systems for accuracy, 
reproducibility, sensitivity and specificity in the context in 
which they are prescribed for use. Most medical laboratory 
equipment validations in Kenya have mainly been done in an 
ISO 15189 accredited laboratory without factoring in the 
actual working dynamics of non-accredited laboratories 
which comprise of approximately 99% of laboratories     
in Kenya [20]. In this study, we validated the BD 
FACSPresto™, point-of-care equipment, in a typical 
laboratory setting in Kenya (Mbagathi Hospital) against the 
BD FACSCalibur™ (for CD4) and the Mindray BC-5380 
haematology analyser (for Hb) which are standard of care 
devices. Initial validation in similar settings [20, 21] 
involved calculation of misclassification around 350 cells/µl 
as the clinical cut-off as opposed to the normal range of >500 
cells/µl as proposed in the new test and treat ART guidelines. 
This study verified not only the relative bias of BD 
FACSPresto™ against BD FACSCalibur™ in terms of 
absolute CD4 and %CD4 but also Hb measurement which 
was missing in the similar field evaluations [21] using the 
Mindray BC-5380 haematology analyser as the reference. 
This verification was done to determine misclassification, 
sensitivity and specificity of HB and CD4 test around 500 
cells/µl; the clinical cut-off recommended for differential 
care in the new Kenya ART guidelines. 
2. Materials and Methods 
2.1. Study Design and Population 
This study was conducted at Mbagathi Hospital and was 
divided into two parts (Equipment validation and sample 
type validation). The first part involved instrument 
comparison of the point of care device, BD FACSPresto™, 
against the gold standard BD FACSCalibur™ and Mindray 
BC-5380 haematology analyser using venous sample type. 
The second part was to compare venous against capillary 
blood sample types using BD FACSPresto™ for CD4 and 
Hb measurement. Determination of the sample size to use in 
validation was based on exceeding by 25% the minimum 
enrolment recommended by the Clinical Laboratory 
Standards Institute (CLSI) and Good Clinical Laboratory 
Practice (GCLP) guidelines requirement for laboratory assay 
method validations. 
2.2. Sample Collection and Analysis 
Written consent was obtained from 102 HIV-infected 
patients attending the Maternal and Child Health (MCH) 
clinic at the Mbagathi District Hospital for their routine 
follow-up. Their participation involved volunteering to 
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provide both venous and capillary blood samples. Health 
care facility staff trained in phlebotomy collected blood 
specimens as previously described [20]. The samples were 
collected between 31st October and 23rd November 2015. 
Capillary specimens were analysed immediately using the 
BD FACSPresto for research use while EDTA venous blood 
samples were analysed on the BD FACSCalibur™, BD 
FACSPresto™ and Mindray BC-5380 haematology analyser. 
Results obtained from the BD FACSPresto device were 
intended for research use only and were not used for clinical 
patient management. All procedures were conducted under 
Good Clinical Laboratory Practices and Good clinical 
practice guidelines to ensure quality of laboratory testing, 
safety and confidentiality of subjects participating in the 
study and quality of results. 
2.3. Statistical Analysis 
The accuracy and precision performance of BD 
FACSPresto™ system was assessed by comparing its CD4 
count results against the FACSCalibur™ results (Gold 
standard) using venous samples. Further assessment of the 
new system was done by comparing the performance of the 
new system using two different sample types; venous blood 
(Gold) and capillary blood (New) for 102 blood samples. 
The comparison involved both the CD4 count and percent 
results. For Hb, we compared results obtained from Mindray 
BC series hematology analyzer using venous blood samples 
to those obtained from BD FACSPresto™ system using 
capillary blood samples. 
To assess accuracy, correlation and linear regression 
analyses were reported. Bias was also reported using 
Bland‐Altman analysis in which the difference between the 
two methods of measurement was plotted against their mean. 
The limit of agreement was calculated as the mean ± 1.96 
Standard Deviation (SD) of the differences of the results 
obtained. Misclassification rates around clinical cut-offs 
were also reported to measure accuracy. The CD4 results 
were categorized into two categories low CD4 values (<200 
and <500 cells/μl) and normal CD4 values (≥500 cells/μl and 
≥200 cells/μl) for absolute CD4 count and low CD4% (<25%) 
and normal CD4 % (≥25%) for CD4 percent [6]. Standard 
deviation and coefficient of variation (CV) were reported as 
a measure precision.  
Paired sample t-test was used to determine if there is a 
significant difference between the results from the two 
systems or between the different blood samples on the new 
system since the sample types are from the same individual. 
Statistical analysis was done using R program. 
Stepwise analysis for precision and accuracy 
measurements were performed as follows 
a) The first phase was equipment validation at national 
HIV reference laboratory. 
  For precision analysis, we used use venous results 
from BD FACSCalibur™ to split the sample into low 
CD4 values (<200 and <500 cells/μl) and samples of 
normal CD4 values (≥500 cells/μl and ≥200 cells/μl)). 
Absolute mean of CD4 values, standard deviation and 
coefficient of variation were then calculated and 
evaluated for acceptability of the new method (BD 
FACSPresto™). This was to ascertain the 
performance of the new equipment.  
  For accuracy measurement, we used venous samples 
to split the sample into low CD4 values (<200 and 
<500 cells/μl) or percent values < 25% and samples of 
normal CD4 values (≥500 cells/μl and ≥200 cells/μl) 
or percent values > 25%). We then compared the data 
set by graphing; the slope and y-intercept of the 
best-fit line were then calculated using linear 
regression. We finally determined the p-value to 
determine whether there was correlation. 
b) The second phase was field evaluation which involved 
deploying the equipment at Mbagathi hospital which is a non 
ISO accredited laboratory to capture the testing dynamics of 
using this equipment in a non ISO15189 accredited 
laboratory and the probable variation that could be observed 
when capillary sample type was used as opposed to the usual 
venous blood draw. 
  For precision analysis, we used venous samples to 
split the sample into low CD4 values (<200 and <500 
cells/μl) and samples of normal CD4 values (≥500 
cells/μl and ≥200 cells/μl). We then determined the 
absolute mean values for the two sample type, 
standard deviation and coefficient of variation as a 
verification process of the suitability of the new 
sample type.  
  For accuracy measurement, we used venous samples 
to split the sample into low CD4 values (<200 and 
<500 cells/μl) or percent values < 25% and samples of 
normal CD4 values (≥500 cells/μl and ≥200 cells/μl) 
or percent values > 25%). We then compared the data 
set by graphing. The slope and y-intercept of the 
best-fit line were then calculated using linear 
regression. Finally p-value was determined to 
ascertain whether there was correlation. 
c) For Hb measurement, we determined the accuracy and 
precision of the BD FACSPresto™ by comparing its 
capillary BD FACSPresto™ results to the gold standard 
venous sample type Mindray BC series hematology analyzer 
at Mbagathi hospital laboratory. 
d) Data acceptance criteria 
  For CD4 and CD8 absolute values, the 95% 
confidence interval (CI) of the mean difference 
between the test and the reference systems should be ± 
10%. 
  For CD4 and CD8 percent values, the 95% CI of the 
mean difference between test and reference systems 
should be within an absolute ± 3% or a relative ± 10% 
of the reference system, whichever is greater. 
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3. Results  
102 people were involved each giving both the capillary 
and venous sample type. All capillary blood specimens had a 
corresponding venous sample from the same subject. The 
blood samples were tested on the FACSPresto™ and the 
FACSCalibur™. 
a) Comparison between FACSCalibur™ and 
FACSPresto™ using venous blood sample 
Table 1 contains summary statistics for absolute CD4 
count analysed on FACSPresto™ and FACSCalibur™. The 
mean CD4 counts were 757.23 (372.091) and 834.38 
(449.561) for FACSPresto™ and FACSCalibur™ 
respectively. There was a significant difference in the mean 
of the CD4 count results from the two systems with a mean 
bias of 77.16 cells/ mL (95%CI (49.89, 104.42), P <0.01). 
This indicates that the FACSPresto™ generated significantly 
lower CD4 counts values compared to the FACSCalibur™ 
especially for the patients with normal CD4 count values. 
See Table 2 for CD4 count summary statistics at different 
clinical CD4 count thresholds. Figure 1 shows bias results 
from the Bland-Altman analysis and correlation and 
regression results on a scatter plot. The mean bias and limits 
of agreements were 77.16 cell/μl and -200.47 cell/mL     
to 354.81 cell/μl respectively. The correlation analysis 
indicates a strong positive correlation (r=0.96, p < 0.001) 
between the CD4 values generated by the two technologies. 
There was 94.11% overall agreement with sensitivity, 
specificity, PPV and NPV at 94.74%, 92.31%, 97.3%       
and 85.72% respectively for FACSPresto™ using 
FACSCalibur™ as the gold standard. Using 200 cells/ μl as a 
threshold, the overall agreement was 95.1% with sensitivity, 
specificity, PPV and NPV at 97.8%, 66.67%, 96.8% and 
75.00% respectively. These results are shown in Table 3.  
Table 1.  Summary statistics for venous blood results using both BD FACSCalibur™ and BD FACSPresto™ 
Technology Mean 95% CI for Mean (LL, UL) 
Std. 
Deviation Minimum Maximum CV 
CD4 Abs. BD FACSPresto™ 757.23 (684.14, 830.31) 372.091 62 1586 49.14 
CD4 Abs BD FACSCalibur™ 834.38 (746.08, 922.68) 449.561 70 1810 53.88 
Difference (BD FACSCalibur™ 
- BD FACSPresto™) 77.1569 (49.89, 104.42) 138.82340 -421.00 469.00 179.92 
Table 2.  Descriptive venous blood subdivided into various CD4 count ranges using BD FACS Calibur and BD FACSPresto™  
Technology CD4 categories N Mean 95% CI for the mean(LL, UL) 
Std. 
Deviation Minimum Maximum CV 
CD4 Abs. FACSPresto™ 
Normal (>=500) 74 928.35 (863.96, 992.74) 277.928 516 1586 29.94 
Low (<500) 28 304.96 (254.8, 355.06) 129.193 62 490 42.36 
CD4 Abs FACSCalibur™ 
Normal (>=500) 76 1030.84 (953.92, 1107.77) 336.627 515 1810 32.66 
Low (<500) 26 260.12 (208.63, 127.46) 127.46 70 477 49 
CD4 Abs. FACSPresto™ 
Normal (>=200) 94 809.43 (739.96,878.89) 339.17 235 1586 41.9 
Low (<200) 8 143.88 (99.91,187.84) 52.59 62 197 36.55 
CD4 Abs FACSCalibur™ 
Normal (>=200) 93 903.67 (819.56,987.77) 408.38 207 1810 45.19 
Low (<200) 9 118.44 (91.07,145.82) 35.61 70 161 30.07 
 
Figure 1.  Comparison between FACSPresto™ and FACSCalibur™. (A) Bland‐Altman indicates mean bias between absolute CD4 counts obtained on 
FACSPresto™ compared with those obtained on the FACSCalibur™. (B) Regression plot comparison of absolute CD4 count obtained from FACSPresto™ 
with the FACSCalibur™ as reference standard 
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Table 3.  Sensitivity, Specificity, Positive Predictive Value (PPV) and Negative Predictive Values (NPV) and misclassification rates of absolute CD4 count 




































































































500 cells/μl           
Absolute CD4 Presto Calibur 94.11% 94.74% 5.26% 92.31% 7.69% 97.3% 85.72% 5.89% 
Absolute CD4 Capillary Venous 97.06% 97.40% 2.60% 96.00% 4.00% 98.00% 92.31% 2.94% 
200 cells/μl           
Absolute CD4 Presto Calibur 95.1% 97.80% 2.20% 66.67% 33.33% 96.81% 75% 4.9% 
Absolute CD4 Capillary Venous 99.02% 98.95% 1.05% 100% 0.00% 100% 87.5% 0.98% 
25%           
CD4 % Capillary Venous 95.10% 95.06% 4.94% 95.34% 4.66% 96.15% 83.33% 4.9% 
Table 4.  Comparison of results using BD FACSPresto™ on venous and capillary blood for the various CD4 count 
Sample type Mean 95% CI for Mean (LL, UL) Std. Deviation Minimum Maximum CV 
Capillary Absolute 864.48 (763.59, 965.37) 513.65 57.00 3674.00 59.42 
Venous Absolute 842.59 (742.95, 942.23) 507.28 70.00 3590.00 60.20 
(Venous-Capillary) Abs CD4 -21.89 (-39.09, -4.70) 87.54 -336.00 114.00 -399.85 
Capillary Percentage (%) 34.07 (31.52, 36.62) 12.98 4.32 59.07 38.10 
Venous percentage (%) 34.89 (32.31,37.47) 13.13 4.77 60.35 37.63 
(Venous-Capillary) % CD4 .82 (0.07, 1.57) 3.81 -23.11 17.47 464.85 
Table 5.  Comparison of results using BD FACSPresto™ on venous and capillary blood for the various CD4 count ranges 
Sample type Category N Mean 95% CI for Mean Std. Deviation Minimum Maximum CV 
Capillary CD4 Absolute 
Normal (>=500) 76 1058.25 (955.94, 1160.56) 447.728 520 3674 42.3 
Low (<500) 26 298.08 (245.85, 350.3) 129.306 57 499 43.4 
Venous CD4 Absolute 
Normal (>=500) 77 1021.29 (918.37, 1124.2) 453.432 505 3590 44.4 
Low (<500) 25 292.2 (243.59, 340.81) 117.751 70 496 40.3 
Capillary CD4 Absolute 
Normal (>=200) 95 918.01 (817.99, 1018.03) 490.99 205 3674 53.48 
Low (<200) 7 138 (85.16, 190.84) 57.13 57 194 41.4 
Venous CD4 Absolute 
Normal (>=200) 94 901.45 (802.24, 1000.65) 484.37 241 3590 53.73 
Low (<200) 8 151 (106.66, 195.34) 53.04 70 198 35.13 
Capillary CD4 percentage (%) 
Normal (>=25%) 78 39.913 (38.14, 41.69) 7.8693 25.5 59.1 19.7 
Low (<25%) 24 15.068 (12.4, 17.74) 6.3236 4.3 24.1 42 
Venous CD4 percentage (%) 
Normal (>=25%) 81 40.2577 (38.46, 42.06) 8.13836 26.29 60.35 20.2 
Low (<25%) 21 14.171 (11.36, 16.98) 6.17356 4.77 24.38 43.6 
 
b) Comparison between the results for CD4 count and 
CD4% from Venous and capillary blood on BD 
FACSPresto™ system 
In Table 4, the mean CD4 counts were 864.48 (513.65) 
and 842.59 (507.28) using capillary and venous blood 
samples respectively while that of the CD4 % were 34.07 
(12.98) and 34.89(13.13) using capillary and venous blood 
samples respectively. The mean bias of CD4 count on the 
FACSPresto™ -21.89 cells/ mL (95%CI -39.09, -4.70, P 
<0.013) while that of CD4 percentage was 0.82 cells/ mL 
(95%CI 0.07, 1.57, P <0.032). Table 5 shows the same 
comparison for different CD4 count and CD4 ranges. 
Categorisation has been done at the clinical cut-off of 500 
cells/ml and 200cells/ml. For the %, the classification has 
been done at 25%. There was a slight over quantification of 
the CD4 counts using capillary sample type while the results 
of the CD4% were comparable between the blood samples. 
The Bland-Altman analysis and correlation and regression 
results are shown in Figure 2. CD4 count values for the 
capillary and the venous blood samples are highly correlated 
(r = 0.985, p<0.001) compared to their CD4% values        
(r =0.478, <0.001). The mean bias and limits of agreements 
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for the CD4 count were -21.89 cell/mL and -188.07 cell/mL 
to 162.09 cell/mL respectively while that of the CD4% were 
0.82 % and -6.8%cell/mL to 8.44% respectively (see figure 
2). Using 500 cells/ml to compare the Venous blood and 
Capillary blood using CD4 count on FACSPresto™, the 
overall agreement, sensitivity, specificity, PPV and NPV 
were found to be 97.06%, 97.40%, 96.00%, 98.0 and 92.3% 
respectively while those for a threshold of 200 cells/ml were 
99.02%, 98.98%, 100.00%, 100.00% and 87.8% respectively. 
The overall agreement, sensitivity, specificity, PPV and 
NPV for the CD4 percent threshold of 25% were 95.10%, 
95.06%, 95.34%, 96.15%, and 83.33% respectively. These 
results are presented in Table 3 above. 
Further comparison was done on the CD4 counts results 
generated by the BD FACSCalibur™ on venous blood 
samples and BD FACSPresto™ on capillary blood samples. 
Summary statistics are shown on Table 6. The mean CD4 
counts were 864.48 (513.65) and 834.38 (449.561) for 
capillary and venous blood samples respectively. There was 
no significant difference in the mean of CD4 count results 
from the two results with a mean bias of -30.10 cells/ μl 
(95%CI (-82.45, 22.23), P = 0.257). The bias results are 
almost similar even when CD4 counts were categorized into 
two groups using both 200 cells/ μl and 500 cells/ mL as 
thresholds for CD4 counts (see Table 7). Correlation analysis 
on Figure 3 indicates existence of correlation between the 
results generated by the BD FACSCalibur™ on venous 
blood samples and BD FACSPresto™ on capillary blood 
samples (r = 0.86, p< 0.01). In Figure 4, the overall 
agreement, sensitivity, specificity, PPV and NPV for the 
CD4 counts at a threshold of 500 cells/ μl were 94.12%, 
96.05%, 88.46%, 96.0%, and 88.4%, respectively while the 
results at 200 cell/ μl threshold were 96.08%, 98.92%, 
66.67%, 96.8% and 85.7% respectively.  
 
 
Figure 2.  Comparison between Venous and Capillary samples on FACSPresto™. Bland‐Altman indicates mean bias between absolute CD4 counts (A) 
and CD4% values (C) obtained on using venous samples compared with those obtained using capillary samples on FACSPresto™. Regression plot 
comparison of absolute CD4 counts (B) and CD4% values (D) count obtained on using venous samples compared with those obtained using capillary 
samples on FACSPresto™ 
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Table 6.  Summarized descriptive statistics for the results from BD FACSCalibur™ on venous blood and BD FACSPresto™ on capillary blood samples 
Blood sample (Technology) Mean 95% CI for Mean (LL, UL) 
Std. 
Deviation Minimum Maximum CV 
Capillary (BD FACSPresto™) 864.48 (763.59, 965.37) 513.65 57.00 3674.00 59.42 
Venous (FACSCalibur™) 834.38 (746.08, 922.68) 449.561 70 1810 53.88 
Difference (Venous (FACSCalibur™) – Capillary      
(BD FACSPresto™)) -30.10 (-82.45, 22.23) 266.56 -2154 293 885.58 
Table 7.  Comparison of results using BD FACSCalibur™ on venous blood and BD FACSPresto™ on capillary blood for the various CD4 count ranges 




Normal (>=500) 76 1058.25 (955.94, 1160.56) 447.728 520 3674 42.3 




Normal (>=200) 95 918.01 (817.99, 1018.03) 490.99 205 3674 53.48 




Normal (>=500) 76 1030.84 (953.92, 1107.77) 336.627 515 1810 32.66 




Normal (>=200) 93 903.67 (819.56, 987.77) 408.38 207 1810 45.19 
Low (<200) 9 118.44 (91.07, 145.82) 35.61 70 161 30.07 
Table 8.  Sensitivity, Specificity, Positive Predictive Value (PPV) and Negative Predictive Values (NPV) and misclassification rates of absolute CD4 count 



































Table 7.  Summary statistics of the HB results using BD FACSPresto™ on venous and capillary blood  
Blood sample Mean 95% CI for Mean (LL,UL) Std. Deviation Minimum Maximum CV 
Mindray BC Venous - Mbagathi 12.83 (12.33, 13.34) 2.58 3.10 18.00 4.97 
BD FACSPresto™ - Capillary-Mbagathi 12.52 (11.99, 13.05) 2.7 3.60 18.30 4.64 
 
Figure 3.  Comparison between Venous (FACSCalibur™) and Capillary (FACSPresto™). (A) Bland‐Altman indicates mean bias between absolute CD4 
counts using venous samples on FACSCalibur™ compared with those obtained using capillary samples on FACSPresto™. (B) Regression plot comparison 
of absolute CD4 counts values obtained on venous samples on FACSCalibur™ compared with those obtained using capillary samples on FACSPresto™ 




Figure 4.  Comparison between Mindray BC Venous sample result and FACSPresto™ capillary samples results on (A) Bland‐Altman indicates 
mean bias between HB concentrate values obtained on using venous samples on Mindray BC to those obtained using capillary samples on FACSPresto™.  
(B) Regression plot comparison of HB concentrate values count obtained on using venous samples on Mindray BC compared with those obtained using 
capillary samples on FACSPresto™ 
 
Comparison of the HB results using BD FACSPresto™ 
on venous and capillary blood 
Table 7: Has the summary results for the HB 
concentration analysis. The mean HB values were 12.8 (2.58) 
and 12.52 (2.70) for Venous and capillary samples 
respectively. The HB results from the two blood samples 
were found to be significantly different with a mean HB 
difference being -0.31 (p value = 0.004). There was however 
a high correlation between the results from the two systems 
at a correlation coefficient of 0.920 (P< 0.001). 
4. Discussion  
BD FACSPresto™ is a new point of care testing 
equipment meant to support CD4 testing program in Kenya. 
Initially the country had FACSCalibur™. We found that 
there was a significant difference in mean CD4 absolute 
values between BD FACSPresto™ and FACSCalibur at 
p<0.01. In terms of sample type interchangeability within 
BD FACSPresto™, there was a significant difference 
between venous and capillary sample type at p<0.013 with 
capillary giving higher values as compared to venous (-21.89 
cells/ μl (95%CI -39.09, -4.70)). For sample type comparison 
within BD FACSPresto™, we found that sensitivity, 
specificity, upward misclassification, downward 
misclassification, PPV and NPV were 94.40%, 96.0%, 
2.60%, 4.00%, 98.0% and 92.3% respectively. Additionally 
when we compared capillary BD FACSPresto™ to venous 
FACSCalibur™, we found out that there was no significant 
difference at p=0.257. This indicates that capillary sample 
type is the ideal sample type for use in BD FACSPresto™. 
For Hb measurement, there was no significant difference 
between BD FACSPresto™ and Mindray BC with difference 
in absolute mean of -0.31 and a p value of P<0.001. 
This study evaluated the performance characteristics of 
this analyzer, under ideal laboratory conditions using both 
venous and capillary blood sampling, as well as its 
applicability in a typical health care clinic to support both 
CD4 and Hb testing using FACSCalibur™ and Mindray BC 
as the gold standard method of testing. Capillary ‘finger stick’ 
blood is the ideal sample type for BD FACSPresto™ in 
terms of reliable CD4 and Hb reporting for patients on ART 
program. Similar studies have reported good correlation 
ranging from 0.890 to 0.992 under ISO 15189 certified 
laboratory conditions while varying accuracy and 
consistency has been reported for capillary sample collection 
method under field condition [16, 22-26]. This compares 
with our findings of r being equivalent to 0.985. 
Venous blood CD4 result comparison of FACSCalibur™ 
and FACSPresto™ reported here are similar to previous 
reports where venous sampling was used [22, 27-30]. In 
these studies, the mean difference in absolute CD4 values 
ranges from of 62.17 to 116.79 cells/mL. All these studies 
report a significant difference similar to our study at a 
p-value of P <0.01. For sensitivity and specificity, the 
FACSPresto™ results were 94.74% and 92.3%. For  
program planning this is equivalent to population    
upward misclassification of 5.26% and 7.69% downward 
misclassification for absolute CD4 count.  
Capillary sampling and testing by FACSPresto™ 
compared well with the venous FACSPresto™ method, with 
a small overestimation of absolute counts, the difference in 
mean absolute values was 21.89 cells/mL (95%CI -39.09, 
-4.70) and a p value of P <0.013. Regression analysis of the 
absolute values gave an r of, r=0.985 and P< 0.013. For 
sensitivity and specificity, the FACSPresto™ results were 
94.40% and 96.0%. For program planning this is equivalent 
to population upward misclassification of 2.60% and 4.00% 
downward misclassification for absolute CD4 count. The 
result was not different when the clinical cut-off was set at 
500 cells/ml or 200 cells/ μl. This underpins the tight 
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difference between the capillary Presto™ and venous 
Presto™. This was not different from the CD4 % comparison 
that had a mean difference of 0.82% cells/mL (95%CI 0.07, 
1.57) with a p value of P <0.032 and r value of (r=0.958,   
P< 0.032) indicating good correlation between the two 
platforms. This was similar to other study findings; despite 
small mean Bland Altman bias reported giving the 
impression of minimal difference, wide limits of agreement 
have been reported in most studies, confirmed in a large 
recent meta-analysis [4, 5, 12, 30]. Preliminary findings 
from other cartridge-based systems like Daktari and MBio 
reveals under-estimation of absolute CD4 counts using 
venous sampling and relatively poor precision to 
FACSCalibur™ [28, 29, 31]. 
For Hb measurement, FACSPresto™ capillary blood Hb 
result compared fairly with venous Mindray BC results as 
reported by similar studies [32-37]. These other studies had 
mean absolute values ranging from -0.41 to 0.37 while the 
correlation ranged from r = 0.876 to r= 0.983 at P< 0.001. 
5. Conclusions 
The results obtained from the capillary BD FACSPresto™ 
were comparable to the standard venous BD FACSCalibur™ 
and Mindray BC-5380 haematology analyser while venous 
BD FACSPresto™ underestimates the absolute CD4 count. 
The capillary BD FACSPresto™ can therefore be utilized to 
measure CD4 and Haemoglobin in HIV patients especially in 
resource limited settings. The system can facilitate testing of 
~50 samples per day for both CD4 and Hb measurement 
from a finger prick capillary sample making it an ideal 
sample type for use in the field or to extend laboratory 
services where resources are limited or access to laboratories 
is poor. In comparison on the best POCT to use in the market, 
we advise various stakeholders to conduct a cost-effective 
analysis studies of available platform before deciding on the 
ideal platform for each population. 
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